it is opposite Rebecca. The early approval process is only for rare diseases as defined by less than 200,000 in the US. What I remember is it is important to have treated enough patients for reliable safety data. Sometimes they require a post approval P3. There is even a possibility of approval right out of phase 2. if the results of 201 are spectacular.
What to hopefully look forward too, page-23
-
- There are more pages in this discussion • 17 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.96M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.4¢ | 0.2¢ | $36.94K | 11.98M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 741680 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 152086887 | 65 |
View Market Depth
| Last trade - 16.10pm 05/11/2024 (20 minute delay) ? |
| ATH (ASX) Chart |